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Abstract
The adverse consequences of developmental exposures to perfluorooctanoic acid (PFOA) are
established in mice, and include impaired development of the mammary gland (MG). However,
the relationships between timing or route of exposure, and consequences in the MG have not been
characterized. To address the effects of these variables on the onset and persistence of MG effects
in female offspring, timed pregnant CD-1 dams received PFOA by oral gavage over various
gestational durations. Cross-fostering studies identified the 5 mg/kg dose, under either lactational-
or intrauterine-only exposures, to delay MG development as early as postnatal day (PND) 1,
persisting beyond PND 63. Intrauterine exposure during the final days of pregnancy caused
adverse MG developmental effects similar to that of extended gestational exposures. These studies
confirm a window of MG sensitivity in late fetal and early neonatal life, and demonstrate
developmental PFOA exposure results in early and persistent MG effects, suggesting permanent
consequences.
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1. Introduction
Perfluorooctanoic acid (PFOA) is a broadly used industrial compound, as well as a final
environmental degradation product of many other perfluorinated compounds. Numerous
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applications of PFOA arise from its capacity to resist extreme temperatures and stresses, and
include industrial production of fire-fighting and flame retardant materials, water- and oil-
repellant coatings for fabrics and food packaging, surfactants, paint additives, and electrical
insulation, among many others. However, the chemical properties of PFOA, which lend so
well to these commercial applications, result also in its environmentally persistent nature
[1]. Given its commercial and environmental ubiquity, in conjunction with its persistence, it
is not surprising that PFOA has been detected in the sera of humans and wildlife, and found
to be widely distributed by a number of survey studies [2–9]. Recent estimates suggest that
the non-occupationally exposed American exhibits an average serum PFOA concentration of
3.9 ng/ml, which is down from the national average 2 years prior (5.2 ng/ml) [10]. While
sources of exposure are poorly characterized, this may result from ingestion of contaminated
food or water, as compared to the presumed inhalational route among the occupationally
exposed. This average serum PFOA concentration, to date, has not been associated with
adverse health effects in humans. However, occupationally relevant levels, higher than those
observed in the average American, have been observed in animal toxicity studies [11,12].
Toxicologic studies of carcinogenesis in animals have indicated the potential for high-dose
(generally, >10 mg/kg/day in rodents, chronically), adult PFOA exposures to result in
hepatotoxicity marked by extreme hypertrophy, as well as a common tumor triad consisting
of hepatocellular carcinomas, pancreatic acinar-cell tumors, and Leydig cell tumors [13,14].
Recent developmental toxicity studies in an outbred mouse strain have identified the
capacity for PFOA to hinder early life body weight gain in gestationally exposed offspring
[11,15,16], as well as delay mammary gland (MG) development in female offspring [17]
independent of body growth retardation. Treatment of pregnant dams with 5 mg/kg PFOA
on gestation days (GD) 12–17 was demonstrated as sufficient to produce developmental
delays in the 10- and 20-day-old offspring MG [17]. Whether this response is dependent on
use of this relatively high exposure compared to that received by humans, is specific to late-
pregnancy timing, or requires both in utero and lactational exposures, is not known.
Nevertheless, these routes of exposure have immediate relevance to human health, as PFOA
has been detected in both the cord blood and breast milk of humans [18–24]. Given these
potential human exposures, understanding how these changes in the MG are mediated by
PFOA exposure conditions in the mouse will be critical in interpreting mode of action and
health risk in human populations.
In the three studies described herein, the persistence of the MG effects present in PFOA-
exposed offspring is addressed, as is the timing and route of exposure sufficient to produce
these effects. Utilizing concurrent animals from previously reported studies [11], adult and
late-life consequences of PFOA exposure with respect to MG tissue were examined. Then,
to determine the timing of the appearance of the MG phenotype, another similar experiment
was performed, addressing multiple early time points not included in the prior studies. Using
the resulting data, this paper discusses the onset and duration of impaired MG development
resulting from early-life PFOA exposures, the persistence of this impairment, and the
subsequent late-life MG phenotype.
2. Materials and methods
2.1. PFOA
Perfluorooctanoic acid (PFOA, ammonium salt; >98% pure) was purchased from Fluka
Chemical (Steinhiem, Switzerland). NMR analysis, kindly provided by 3M Company (St.
Paul, MN, USA), indicated that approximately 98.9% of the chemical was straight-chain and
the remaining 1.1% was branched isomers. For all studies, PFOA was dissolved by mild
agitation in de-ionized water and prepared fresh daily, immediately prior to administration.
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All animal studies were conducted in accordance with guidelines established by the National
Health and Environmental Effects Research Laboratory Institutional Animal Care and Use
Committee. Procedures and facilities were consistent with the recommendations of the 1996
NRC “Guide for the Care and Use of Laboratory Animals”, the Animal Welfare Act, and
Public Health Service Policy on the Humane Care and Use of Laboratory Animals. Timed
pregnant CD-1 mice were obtained from Charles River Laboratories (Raleigh, NC, USA),
where females were bred overnight, and the sperm positive females, defined as GD 0, were
shipped on the same day for use in these studies. Upon arrival, mice were housed
individually in polypropylene cages with Alpha-dri (Shepherd Specialty Papers, Kalamazoo,
MI, USA) bedding and provided pellet chow (LabDiet 5001, PMI Nutrition International
LLC, Brent-wood, MO, USA) and tap water (containing PFOA at concentrations below the
level of detection) ad libitum. Animal facilities were controlled for temperature (20–24 °C)
and relative humidity (40–60%), and kept under a 12-h light–dark cycle.
2.3. Late-life effects cross-foster study
The study was performed in two blocks, spaced 4 weeks apart, with 56 timed pregnant mice
per block (112 total). Upon arrival at the animal facility on GD 0, mice were weighed and
randomly assigned to one of three treatment groups, vehicle control which received de-
ionized water (n = 48), 3 mg PFOA/kg body weight (n = 28), or 5 mg PFOA/kg body weight
(n = 36). On GD 1–17, mice were weighed daily and dosed by oral gavage at a 10 ml/kg
volume. On GD 18–19, dams were monitored at 4-h intervals, and litters of similar ages and
exposures were mixed, then fostered to yield the following seven exposure groups shown in
Fig. 1A: (1) control pups nursed by control dams (control); (2) control pups nursed by dams
dosed during gestation with 3 mg PFOA/kg (3L, lactational exposure); (3) control pups
nursed by dams dosed during gestation with 5 mg PFOA/kg (5L, lactational exposure); (4)
pups exposed in utero to 3 mg PFOA/kg nursed by control dams (3U, intrauterine exposure);
(5) pups exposed in utero to 5 mg PFOA/kg nursed by control dams (5U, intrauterine
exposure); (6) pups exposed in utero to 3 mg PFOA/kg nursed by dams dosed during
gestation with 3 mg PFOA/kg (3U + L, intrauterine and lactational exposure); (7) pups
exposed in utero to 5 mg PFOA/kg nursed by dams dosed during gestation with 5 mg
PFOA/kg (5U + L, intrauterine and lactational exposure). Foster litters included 10 pups
with equal representation of males and females (where possible). All pups were either
assigned to foster litters or were euthanized.
2.4. Early-life effects cross-foster study
The study was performed in a single block of 112 timed-pregnant CD-1 mice. Upon arrival
at the animal facility on GD 0, mice were weighed and randomly assigned to one of two
treatment groups, either vehicle control which received deionized water (n = 56) or 5 mg
PFOA/kg body weight (n = 56), received by oral gavage. Pregnant dams were weighed daily
and dosed by oral gavage at a 10 ml/kg volume on GD 8–17, as this treatment window was
previously demonstrated as sufficient to impair offspring MG development without
profound offspring growth deficits or postnatal loss [17]. On GD 18–19, dams were
monitored at 4-h intervals, and litters of similar ages and exposures were mixed, then
fostered to yield the following four exposure groups shown in Fig. 1B: (1) control pups
nursed by control dams (control); (2) control pups nursed by dams dosed during gestation
with 5 mg PFOA/kg (5L; lactational exposure of offspring); (3) pups exposed in utero to 5
mg PFOA/kg nursed by control dams (5U, intrauterine exposure of offspring); (4) pups
exposed in utero to 5 mg PFOA/kg nursed by dams dosed during gestation with 5 mg
PFOA/kg (5U + L, intrauterine and lactational exposure of offspring). Foster litters included
10 pups with equal representation of males and females (where possible). All pups were
either assigned to foster litters or were euthanized.
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Sixty-four timed pregnant CD-1 mice were received on GD 0. Mice were weighed and
randomly assigned to treatment groups, and dosed orally by gavage as follows: vehicle
control dosed with de-ionized water at 10 ml/kg on GD 7–17 (n = 12); 5 mg PFOA/kg on
GD 7–17 (n = 14), GD 10–17 (n = 14), GD 13–17 (n = 12), or GD 15–17 (n = 12), as shown
in Fig. 1C. The study did not include the GD 1–17 dosing window, as this was addressed in
the 5U + L dose group in the late-life effects cross-foster study, performed within weeks of
this study. On GD 18–19, mice were monitored at frequent intervals until parturition and the
date and time of birth, number of live and dead pups, and number of pups of each sex were
recorded and litters were weighed by sex. Litters were culled to 10 pups with equal
representation of male and female (where possible).
2.6. Postnatal observations and necropsy
For the early-life effects cross-foster study, litters were observed, weighed, and euthanized
on PND 1, 3, 5, and 10 (n = 4 litters per treatment group, per time point). All dams and
offspring in this study were euthanized on or before PND 10. In the late-life effects cross-
foster and restricted-exposure studies, litters were observed as previously described [11]. On
PND 22, pups from the two latter studies were weighed and weaned, and males and females
were housed separately. From these studies, female offspring were necropsied on PND 22,
29, 32, 42, and 62, as well as at 18 months postnatally. At necropsy in all studies, body and
liver weight measurements were made, and whole livers and blood samples were collected.
Serum was prepared from blood samples and stored frozen for PFOA analysis (due to
limited volume, female pup blood was pooled by litter at necropsies which occurred prior to
weaning). The fourth and fifth inguinal MG were collected from dams in the early-life
effects cross-foster study and female offspring in all three studies. MG tissue from one side
of the animal was prepared as a whole mount, and the contralateral glands were prepared for
histological analysis.
2.7. Mammary gland preparations
MG tissues isolated at necropsy for whole mount purposes were mounted flat on glass
slides. Whole mounts were then fixed in Carnoy’s solution, stained in carmine alum stain,
and dehydrated and cleared in xylene, as previously described [25]. A portion of the
contralateral MG was removed, placed in a histology cassette, and fixed in 10% neutral
buffered formalin for 48 h, then stored in 70% ethanol. These histologically prepared glands
were paraffin-embedded, and 5 μm sections were prepared and stained with hematoxylin
and eosin (H&E).
Whole mounts were visualized by light macroscope (Leica WILD M420 macroscope, Leica,
Wetzlar, Germany; magnification up to 70×). MG whole mounts from female offspring
between PND 1 and PND 63 were scored on a 1–4 subjective, age-adjusted, developmental
scale (as described in [26]; 1 = poor development/structure; 4 = normal development/
structure, given age). Briefly, the developing tissue was assessed for the gross presence and
appropriate timing of several histological criteria, including primary ducts and large
secondary ducts, lateral side branching, appearance of budding from the ductal tree,
longitudinal outgrowth of the epithelium, terminal end buds, differentiated ends, and contact
inhibition between glands. Slides were separated by score as they were evaluated, compared
within a score for consistency, and then recorded. Two independent scorers, blind to
treatment, scored glands within the age groups. Mean scores for the time points, within
treatment groups, were calculated and analyzed statistically for treatment and time-related
differences.
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Whole mounts from 18-month-old offspring and lactating dams were qualitatively examined
with respect to concurrent controls. Areas of unusual, darkly staining foci in 18-month-old
tissues were counted. Lactating glands were assessed for differentiation, amount of epithelial
tissue filling the gland, and presence of well-formed, productive alveoli. Representative
tissues from these assessments, as well as those scored by the above-described methods
were photographed using the Leica macroscope and mounted camera (Photometrics
CoolSNAP, Roper Scientific, Inc., Tucson, AZ). Histological sections were visualized by
light microscope (Nikon Eclipse E600, Nikon, Tokyo, Japan), and were assessed by a
pathologist for inflammation, preneoplastic lesions, and areas of hyperplasia, which might
contribute to the aforementioned unusual foci. Magnifications are shown in figures.
Photographs were taken using a Nikon FDX-35 scope-mounted camera.
2.8. Serum PFOA determination
Serum samples from the dams and pups of the early-life effects cross-foster study (at PND
1, 3, 5, and 10), pups of the restricted-exposure study (at PND 22, 29, and 32), and 18-
month-old female offspring from the late-life effects cross-foster study were prepared at the
Environmental Protection Agency. All serum samples were stored frozen in polypropylene
vials, shipped on dry ice to the Centers for Disease Control and Prevention’s National
Center for Environmental Health laboratory, and then kept at or below −40 °C until analysis.
Measurement of the concentrations of PFOA in serum was performed through a multiple
reaction monitoring experiment using a modification of the online solid-phase extraction
(SPE) coupled to reversed-phase high-performance liquid chromatography (HPLC)–tandem
mass spectrometry previously described [27]. A Surveyor HPLC pump (ThermoFinnigan,
San Jose, CA, USA) was used, coupled with a ThermoFinnigan TSQ Quantum Ultra triple-
quadrupole mass spectrometer equipped with a heated electrospray ionization (HESI)
interface. The HPLC pump operated at a 300 μl/min flow rate with 20 mM ammonium
acetate (pH 4) in water (mobile phase A) and acetonitrile (mobile phase B). Necessary
dilution of the serum samples was performed in two steps. First, at least 10 μl serum was
diluted to 0.5 ml with water in a 2-ml Eppendorf tube, then a second dilution was performed
by aliquoting the appropriate amount of the diluent into an autosampler vial, adding 0.1 M
formic acid, and injected into a commercial column switching system allowing for
concentration of PFOA on a C18 SPE column. The column was automatically positioned in
front of a Betasil C8 analytical HPLC column (2.1 mm × 50 mm, 5 μm; ThermoHypersil-
Keystone, Bellefonte, PA, USA) for chromatographic identification of PFOA. Detection and
quantification utilized negative-ion HESI, a variant of electrospray ionization, tandem mass
spectrometry. The isotope-labeled internal standard used for quantification was 13C2 -PFOA.
Blanks and quality control materials, prepared in calf serum, were analyzed along with each
batch of samples to ensure the accuracy and reliability of the data across time [27].
2.9. Statistical analysis
Data were evaluated for age and exposure period effects using mixed-model analysis of
variance (ANOVA) in SAS 9.1 (SAS Institute, Inc., Cary, NC). Block effects were not
detected in any test and therefore block was removed from the model. For all measurements,
means were evaluated and effects of dose and exposure periods compared. Statistical
analysis of body weight and maternal effects for the late-life effects cross-foster study and
restricted exposure study were performed as previously described [11]. In the early-life
effects cross-foster study, treatment-specific mean body weights were calculated for dams at
GD 1 and GD 17, and for pups, with litter as the unit of measure, on PND 1, 3, 5, and 10.
For all three studies, mean MG developmental scores were calculated. MG scores were
analyzed using body weight at time of collection as a random effect, with litter as the unit of
measure for neonatal scores. Differences between treatment groups were determined using
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Dunnett’s or Tukey’s t-tests (significance at the level of p < 0.05 for all comparisons, in text
and figures), with SAS.
3. Results
3.1. Late-life effects cross-foster study
As previously reported, all exposed groups exhibited lower body weight compared to
controls at PND 22, except 3L [11]. These deficits were overcome within one week
subsequent, except among the 5U and 5U + L groups which did not recover until as late as
PND 85 [11]. Additionally, all exposed groups exhibited increased liver to body weight
ratios at weaning [11], presumed to result from liver hypertrophy, as observed in adult-
treated animals. In the present study, at PND 22, 42, and 63 (that is, 3-, 6- and 9-weeks-old)
all cross-fostered offspring that received PFOA exposure, regardless of route or dose,
exhibited reduced MG developmental scores, as compared to controls, except for the 3L
group at PND 22, and the 3U + L group at PND 42 (Table 1). This abnormal development
was characterized by delays in ductal elongation, delays in timing of terminal end bud
(TEB) appearance, and reduced secondary and tertiary branching (Fig. 2A). Reduced
branching was particularly pronounced among the combined exposure groups (3U + L, not
shown; 5U + L), which exhibited mammary fat pads with greatly reduced parenchymal
density (not reflected in 3U + L score at PND 42, due to inter-individual variance and the
multiple criteria used to arrive at the final score). While PFOA-exposed groups at most time
points exhibited lower MG developmental scores compared to controls, there was no
consistent trend that suggested that any one exposure route (5L vs. 5U), or dose given via an
exposure route (3L vs. 5L) negatively affected MG development more than the others.
In female offspring from this study at 18-month postnatally, MG development could not be
assessed using the scoring criteria described. However, as seen in Fig. 2B, the epithelial
density within a gland appeared to be reduced in PFOA-exposed animals, particularly
among the combined exposure groups (3U + L, not shown; 5U + L). Ostensibly, this arose
due to a smaller starting population of parenchymal cells, and thus the subsequent reduced
branching and proliferation of that ductal network resulted in sparser epithelial arborization
of the fat pad. Additionally, among PFOA-exposed groups there was a tendency to exhibit
higher densities of unusual, darkly staining foci in an individual gland than observed among
controls (Fig. 2B; mean number of foci per gland: controls = 6.9, 3 mg/kg exposure groups
= 34.3, 5 mg/kg exposure groups = 38.6). In histopathologic MG sections, as shown in Fig.
2B, these darkly staining areas appear to result from one or more of the following:
hyperplasia of the ductal epithelium, infiltration by inflammatory cells into ductal regions,
increases in stromal density surrounding the ducts, or inappropriate differentiation of MG
ductal epithelium (Fig. 2B). These histologic analyses utilized a single section of the
contralateral gland, not that used for whole mounts. As such, the observations described in
histopathologic sections were not in the same tissue in which whole mount observation were
made, and therefore may not explain individual darkly staining foci. In whole mounts, the
composition and etiology of these foci cannot be determined, but it is presumed that
histopathologic MG sections are representative, and therefore reveal what produced the
appearance of these foci. In addition, peripheral, localized increases in epithelial density
were visible in whole mounts of some 18-month-old PFOA-exposed offspring; however,
there was not a consistent effect of dose or route of exposure on the extent of the pathology.
Furthermore, these increases were strictly peripheral, and did not represent an achievement
of ideal epithelial organization and content, which early time points revealed to be delayed
and diminished. This study was not designed to address these histological changes in the
tissue, and therefore these observations are noted, but not interpreted.
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3.2. Early-life effects cross-foster study
Maternal and early neonatal indices were assessed and no effect of treatment was observed
on either litter size or pup birth weight (data not shown). However, dam weight gain during
pregnancy was significantly higher among dams treated with 5 mg/kg PFOA on GD 8–17
(29.2 ± 0.8 g) compared to controls (25.7 ± 1.0 g).
Among all PFOA-exposed offspring, significant delays in MG developmental morphology
were observed as early as PND 1 (Fig. 3), similar to those seen at later time points in the
late-life effects cross-foster study. The lactation-only exposure group nursed on treated dams
and thus were exposed to PFOA for at least 12 h after parturition before the PND 1
necropsy, a period which is marked by very rapid elongation and branching of the early
ductal epithelium, and may be particularly susceptible to insult by circulating PFOA. These
effects persisted through the duration of the study, from PND 1 to 10, among the three
exposed groups as compared to controls (Table 1). Differences in severity of developmental
delays between PFOA exposure groups were only evident at PND 5 when 5U and 5U + L
differed significantly from one another, and at PND 10 when 5L development, despite being
worse than controls, was significantly greater than either 5U or 5U + L, which were both
determined to be severe (defined as a developmental score ≤1.5; Table 1).
None of the PFOA-exposed groups exhibited reduced body weight compared to controls on
PND 1, the age at which both intrauterine-exposed groups exhibited highest circulating
PFOA levels (Table 1; Fig. 4B). While this result differs from that previously reported for
the late-life effects study [11], it is important to note that gestational treatment in the early-
life study did not start until GD 8, as compared to GD 1 in the late-life effects study (Fig. 1A
and B). On PND 3 the combined exposure females (5U + L) weighed less than controls, and
by PND 5 the other exposure groups also weighed less than controls (5L and 5U). It should
be noted that MG developmental scores were consistently lower among PFOA-exposed
offspring over PND 1–10, in the absence of consistent body weight disparities.
Liver to body weight ratios were elevated among intrauterine-exposed pups (5U, 5U + L) on
PND 1, when their serum levels were highest (Table 2; Fig. 4B), suggesting that liver
hypertrophy may be initiated prior to birth. Lactationally exposed pups also exhibited a
significant elevation in this ratio by PND 5, when their circulating PFOA reached
approximately 15,000 ng/ml. By this time point, all PFOA-exposed offspring exhibited
increased relative liver weight, which persisted through PND 10. Considering the effect of
this increased liver weight, adjusted body weights were calculated by subtracting the liver
weight from the body weight of each neonate. Using this adjusted body weight as a random
effect, statistics on MG scores were reevaluated and determined to be unaffected by
potential growth deficits not reflected in whole body weight (data not shown).
Morphological examination of lactating dam MG tissue suggested profoundly altered
differentiation in treated dams (nursed 5L, 5U + L pups) at PND 1, when lobulo-alveolar
units appeared neither distended nor differentiated to the degree of control tissues, and a
large population of adipocytes remained discernable (Fig. 5). Qualitatively, these glands
appeared immature, similar to that seen in late pregnancy, prior to parturition and the
initiation of nursing. Because this phenotype was present in dams nursing controls pups, it
may be presumed that this effect is a direct action of PFOA on the differentiating lactating
dam, rather than a result of possible poor suckling and stimulation by smaller, and
presumably weaker, PFOA-treated pups (as discussed in [17]). While these treated groups
continued to exhibit diminished lactational morphology until PND 10, alveolar units filled
the fat pad more completely by PND 3 though they did not catch up with control dam
morphology before the end of the study (data not shown). Reduced alveolar filling of the fat
pad was visible among control dams nursing treated offspring (5U) as early as PND 3 (data
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not shown), at which time point these dams exhibited serum PFOA levels of roughly 2000
ng/ml (Fig. 4A), presumably as a result of dam behaviors that include grooming the litter
and stimulating micturition, thereby ingesting PFOA eliminated from the offspring. The
precipitous drop in circulating PFOA in 5U pups suggests that the compound, primarily lost
through the urine, is being excreted at a high rate, and could therefore readily be ingested
through normal maternal behaviors. Delays in lactational morphology persisted to PND 10
among these three exposed groups of dams, with combined-exposure dams in the 5U + L
group exhibiting the most profound delays (data not shown).
3.3. Restricted-exposure study
In the restricted-exposure study, treatment with PFOA under even the shortest duration
treatment, GD 15–17, was sufficient to consistently lower MG scores at PND 29 and 32 as
compared to controls (Table 1). These delays, observed in all treatment groups, were similar
to those observed in both cross-foster studies, in that they were marked by reduced ductal
elongation and branching, as well as delays in timing and density of TEBs (control, GD 15–
17, and GD 10–17 shown, Fig. 6A). Because all treated groups except for GD 10–17,
recovered from body weight deficits within 1 week of weaning (previously reported in [11]),
the observed MG delays again occurred in the absence of body weight deficits, which might
otherwise have been a factor in MG growth impairment (except in the GD 10–17 group,
when body weight was still below that of controls).
At 18-month postnatally, MG development was not scored in the fully mature gland, due to
the absence of developmental indices integral to scoring criteria. However, among PFOA-
exposed groups, as with the late-life cross-foster study, there was a tendency for PFOA-
exposed females to exhibit higher densities of unusual darkly staining foci, which were
originally suspected to be areas of ductal hyperplasia (Fig. 6B; mean number of foci per
gland: controls = 1.5, GD 15–17 exposure = 29.8, GD 13–17 exposure = 17.9, GD 10–17 =
32.8, GD 7–17 = 25.5). Identical to that noted in the late-life effects cross-foster study,
observations in histopathologic MG sections (Fig. 6B) suggest these darkly staining foci
result from one or more of the following: hyperplasia of the ductal epithelium, infiltration by
inflammatory cells into ductal regions, increases in stromal density surrounding the ducts, or
inappropriate differentiation of MG ductal epithelium. To a greater degree than the late-life
effects study, peripheral, localized increases in epithelial density were visible in whole
mounts from many 18-month-old PFOA-exposed animals.
Serum PFOA levels were not measured in these animals, though the serum data from the
late-life effects cross-foster study at 18-month demonstrate that serum PFOA are at
background levels. Mean body weights, liver weights, and liver to body weight ratios were
similar between all treatment groups and controls at 18-month postnatally.
3.4. Serum PFOA dosimetry
The serum PFOA concentrations previously reported by Wolf et al. [11] for the late-life
effects cross-foster study should be considered when evaluating the MG scores. Therefore,
the control, 5L, 5U, and 5U + L group means at 3, 6, and 9 weeks [11] are presented in Fig.
4B (3L, 3U, and 3U + L are not shown, but were consistently lower than the 5 mg/kg
equivalent exposure groups). These data appear alongside serum PFOA concentrations
measured in the early-life effects cross-foster study (vide infra) to illustrate the potential
pattern of PFOA serum load over time, based on exposure parameters. However, the early-
life effects study exposure period was about 60% the duration of the late-life study, and
therefore these data cannot be directly compared. Most importantly, in the late-life effects
study the persistent nature of the MG developmental delays was evident at 9 weeks
postnatally, when the circulating PFOA concentrations had returned to near-background
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levels, on the order of hundreds rather than tens of thousands of ng/ml. As presumed, based
on the 16–19 days half-life of PFOA in mice [28], mean serum PFOA concentrations were
similar to controls and had reached background levels in all PFOA-exposed females, 18
months after their last treatment (data not shown).
In the early-life effects cross-foster study, serum PFOA concentrations in female offspring
were highest at the earliest time point assessed, PND 1, among those with intrauterine
exposure (5U, 5U + L; Fig. 4B). Conversely, among the lactationally exposed (5L)
offspring, levels rose steadily after birth and through PND 10, demonstrating substantial
postnatal lactational transfer of PFOA. This transfer was evident also by the decline in
serum PFOA observed in the treated dams that nursed these pups, which exhibited the
highest serum concentrations at PND 1, falling steadily during lactation (Fig. 4A).
Interestingly, at PND 1 the intrauterine-exposed offspring (5U, 5U + L) exhibited
significantly higher serum levels than treated dams, a surprising observation given previous
assumptions about gestational transfer [29]. This trend appeared to diminish with time, and
by PND 10 dam and pup serum levels were similar. Among lactating dams in this study,
serum PFOA concentrations decreased over time between PND 1–10, among the two treated
groups. Control dams that nursed intrauterine-only exposed pups exhibited increasing serum
PFOA over the course of the study, and significantly higher serum PFOA concentrations
than controls as early as PND 1, which persisted through the study.
In the restricted-exposure study, serum PFOA concentrations for all treated groups at PND
29 and 32 (previously reported in [11]) were consistently higher than controls even under
the shortest duration exposure of GD 15–17. While serum PFOA concentrations were not
measured in 18-month-old females from this study, one may presume – given PFOA
pharmacokinetics in the CD-1 mouse [28] – that the serum concentrations for the 18-month-
old 5U + L females in the late-life effects study represent conservative estimates for
circulating PFOA concentrations in females of the same age, strain, and environmental
conditions in the restricted-exposure study, where PFOA dose and route of exposure were
the same, only exposure periods were shorter (Fig. 1A and C). Furthermore, serum PFOA
reported previously for these two studies [11] consistently showed lower serum PFOA
concentrations among all PFOA-treated groups in the restricted-exposure study, as
compared to 5U + L offspring in the late-life effects cross-foster study at PND 22.
4. Discussion
These studies have demonstrated the capacity for both short duration prenatal and
exclusively postnatal, lactational PFOA exposure to delay development of the proliferating
MG in offspring from as early as PND 1, to as late as or later than 9 weeks postnatally.
Furthermore, these delays remain apparent even as the internal PFOA dose drops,
approaching background levels. These data, in conjunction with sparse epithelial filling of
the MG fat pad observed in 18-month-old PFOA-exposed offspring, suggest that early life
exposure may result in permanent effects in the mammary tissue.
In the late-life effects study, lactational-only exposure at 5 mg/kg was sufficient to produce
delays in MG development that persisted from 3 weeks until at least 9 weeks of age, when
sexual maturity has been attained, even though PFOA serum concentrations were relatively
low (<350 ng/ml at 9 weeks), and of the same order of magnitude as concentrations reported
in humans exposed to PFOA occupationally or accidentally, by ingestion of contaminated
drinking water [12]. In this group, body weight deficits were overcome after PND 22 [11],
yet MG developmental deficits persisted, and appeared evident even at 18 months
postnatally. These effects were observed in this group despite receiving exclusively
postnatal exposure. The 3/5U and 3/5U + L groups also exhibited these delays, and although
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body weight deficits among these groups persisted longer, serum PFOA concentrations in
3/5U females were less than or equal to that in 3/5L females for the entire 3–9 weeks of age
window [11]. Even at 18 months postnatally, filling of the gland by epithelium was visibly
different in density and organization, from controls in lactational exposure-only females, as
well as the intrauterine exposure groups.
The early-life effects cross-foster study supported these findings, and all PFOA-exposed
female offspring – 5 L, 5U, and 5U + L –exhibited delayed MG development as early as
PND 1, or at least 12 h after parturition, during which time the MG parenchyma normally
undergoes rapid growth and development [30]. These delays were maintained, and persisted
through PND 10. These studies taken together suggest that MG deficits resulting from
intrauterine, lactational, or combined exposures to PFOA develop at least as early as PND 1,
and persist into sexual maturation. The observations in the early-life effects study also
specifically point to a window of sensitivity for the MG during late fetal and early neonatal
life. Interestingly, among the 3 mg/kg lactationally exposed group in the late-life effects
study, body weight was never reduced compared to controls, yet MG morphology revealed
growth deficits at PND 42 and PND 63 in the absence of any body growth retardation over
life. This suggests that the threshold for effect may be lower for MG developmental delays
as compared to that for body growth deficits, and that the mechanisms responsible for these
effects may differ.
In the restricted-exposure study, similar persistence of MG morphological deficits was
observed, with as short a treatment window as the final 3 days of gestation (GD 15–17)
producing delays visible at PND 29 and PND 32, and persistent morphological changes
visible at 18 months. These findings are consistent with those of the cross-foster studies,
demonstrating the late gestation and early lactation periods as most sensitive for the effects
of PFOA on the MG.
These findings support previous work [17] that reported delays in MG development
resulting from developmental PFOA exposure, independent of body weight deficits. This
work is also in agreement with work on other environmental agents, which indicates that late
fetal and early neonatal MG development is particularly sensitive to environmental insult
(reviewed in [31], where the rodent MG is illustrated to be a suitable model for the human
tissue). Furthermore, this is the first work to the authors’ knowledge that reports effects of
developmental PFOA exposure occurring as late as the postnatal period – via the presumed
lower transmission route of nursing – that persist into adulthood and late-life. An important
finding was also illuminated in the dosimetry data, specifically that offspring with
intrauterine PFOA exposure exhibited higher serum PFOA concentrations on PND 1 than
did the treated dams they nursed on, an observation not previously reported, and vital to the
understanding of the pharmacokinetics of PFOA in the fetus and neonate. It deserves
mention that the reduced MG epithelium phenotype reported here was also recently
observed following postnatal, peripubertal exposure of C57BL/6 (at the dose of 10 mg/kg,
only) and Balb/c mice to PFOA [32, this issue]. The finding of this similar study, that the
response in the MG seems to differ between inbred strains, is noteworthy and merits further
investigation.
At the conclusion of these studies, numerous questions remain unanswered. Understanding
the no observable adverse effect level (NOAEL) and the lowest observable adverse effect
level (LOAEL) in conjunction with internal dosimetry would be beneficial in reducing
uncertainties in the relationship between dose and health effects. Using the data presented
here and elsewhere, pharmacokinetic models may be able to anticipate these doses.
Characterizing the long-term adverse effects of MG perturbations in PFOA exposed
animals, including possible impaired lactational support of litters or altered cancer
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susceptibility also remains to be understood. Finally, how these morphological delays and
subsequent persistent deficits are mediated remains unclear, but will be important in
determining the human health hazard posed by PFOA.
PFOA is a known agonist of the peroxisome proliferator-activated receptor (PPAR) α
isoform (PPARα). Knockout and transgenic mice have provided some clues as to possible
modes of action for PFOA in the MG. In transgenic mouse dams exhibiting constituitively
activated PPARα, normal differentiation of lobular–alveolar units was so profoundly
impaired during lactation, that no offspring survived until weaning [33], suggesting that
altered PPARα-signalling has the potential to greatly interfere with proper functional
differentiation of the lactating gland.
The mode of action responsible for the general growth deficits observed in gestationally
PFOA-exposed mice was recently examined using PPARα knockout mice. These effects –
including impaired postnatal body weight gain, delayed eye opening among pups, and
postnatal mortality – were found to be dependent upon PPARα expression [16].
Interestingly, early prenatal loss did not appear to require PPARα expression. This study did
not examine dam lactation or MG morphology of female offspring, however, studies
addressing these tissues in PPARα knockout mice are currently underway. Of note is the
fact that the PPARα knockout mice do seem to reproduce normally and exhibit normally
developed MG tissue. It is noteworthy that MG effects have been observed to occur in the
absence of growth deficits, which have been identified as PPARα-dependent effects.
Furthermore, because these delays in body weight gain and developmental indices were
shown not to result from lactational exposure only, while MG effects were, there is evidence
that MG developmental effects may not be mediated by a similar mechanism and may
represent a more sensitive endpoint.
While the observations reported here and in previous publications [17] concerning impaired
lactational development of lobular–alveolar units among PFOA-treated dams, agree with
similar observations in publications examining the impact of PPARα agonists on lactation
[33], the authors do not rule out the potential for an upstream event or an entirely PPARα-
independent pathway to be responsible for the MG effects in either the treated dam or the
exposed offspring.
This work has identified the MG as a tissue that is sensitive to developmental perturbation
by PFOA, and may be among the most sensitive endpoints studied to date. In these studies,
when internal dose was examined with respect to effect, a circulating serum concentration of
about 2000 ng/ml appeared sufficient to stimulate the inhibition of developing and
differentiating MG tissue. This is approximately four times the circulating PFOA
concentration found in some non-occupationally exposed populations [12], suggesting that
epidemiologic studies focused on the health effects of PFOA exposure may want to evaluate
women’s ability to exclusively breast feed. With respect to animal studies, knowledge of the
lowest effective doses and the mode of action for the PFOA-induced MG effects will allow
comparison with health results in epidemiological studies that are currently on-going,
including those by the Breast Cancer and Environment Research Centers [34] and by the C8
Science Panel [35] on the human health effects of PFOA. This type of research, in
conjunction with internal dosimetry, should result in less uncertainty in risk assessment.
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Schematic of study design and implementation for (A) the late-life effects cross-foster study,
(B) the early-life effects cross-foster study, and (C) the restricted-exposure study.
White et al. Page 14














MG development of female offspring in the late-life effects cross-foster study. (A) Whole
mount preparations of mammary tissue from female offspring are shown at PND 22 (25×; a
lymph node appears as a large darkly staining object), PND 42 (50×), and PND 63 (50×).
Glands pictured are representative of mean respective scores (given in Table 1; N = 10–13
adult females per treatment group at PND 22, N = 9–18 per group at PND 42, N = 9–17 per
group at PND 63). *Significant treatment effect by ANOVA, compared to control; p < 0.05.
(B) On the left, whole mounts from representative adult female offspring at 18 months of
age (16×). Large arrows indicate unusual, darkly staining foci; one small arrow in 5U
indicates peripheral, localized increases in epithelial density observed in some PFOA-
exposed animals at 18 months. On the right, histopathologic images from contralateral
glands in the same animal show ductal areas that might account for darkly staining foci
observed on whole mounts (400×; N = 5–12 females per group at 18 months). The arrow in
5U identifies an area of inflammation. In 5U + L the large arrow identifies an area of
increased stromal density; the small arrow points to a potentially hyperplastic region of
ductal epithelium. These ductal pathologies were observed in all treatment groups; some
ductal inflammation was also seen in controls.
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MG development of female offspring in the early-life effects cross-foster study. Whole
mount preparations of mammary tissue from female offspring at PND 1, 3, 5 (64×), and
PND 10 (50×). The arrow in 5U + L on PND 1 identifies ductal epithelium. Glands pictured
are representative of mean respective scores (Table 1; N = 4 litters per treatment group at
each time point; three pup glands scored per litter). *Significant treatment effect by
ANOVA, compared to control; p < 0.05.
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Serum PFOA concentrations in dams and female offspring from the early-life effects cross-
foster study (offspring from the late-life effects study also shown on right for comparison;
reported in [14]). Data are shown as mean ± S.E.M. bars; numerical values are shown for
non-zero controls, and for control dams nursing treated pups at PND 1. (A) Among the
dams, direct treatment with PFOA consistently yielded higher serum level than nursing
treated pups (5U) alone. (B) Among offspring, lactationally exposed females (5L) exhibited
serum concentrations that increased until PND 10, when they converged upon
concentrations observed in the intrauterine (5U) and combined exposure (5U + L) groups.
At PND 1, treated pups (5U, 5U + L) exhibited higher serum PFOA concentrations than
treated dams (nursed 5L, 5U + L pups). By PND 10 all exposed offspring groups were
becoming similar to one another in serum concentrations, and were becoming increasingly
similar in serum concentrations to their paired dams. In the late-life effects study (right), by
PND 63 serum from female offspring in all treatment groups were near background levels,
at less than 1000 ng/ml. Statistical comparisons are provided in the text.
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MG differentiation of lactating dams in the early-life effects cross-foster study. Whole
mount preparations of mammary tissue from lactating dams are shown on PND 1, the first
day of lactation (40×). Glands pictured are representative of lactating dams in respective
groups at LD 1 (body weights given in Table 2; N = 4 dams per treatment group at each time
point).
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MG development of female offspring in the restricted-exposure study. (A) Whole mount
preparations of mammary tissue are shown at PND 32 (16×). Glands pictured show
morphology representative of respective treatment groups at given time points (Table 1; N =
10–20 females per treatment group at PND 32). *Significant treatment effect by ANOVA,
compared to control; p < 0.05. (B) On the left, whole mount preparations of mammary tissue
at 18 months of age are shown (16×). Large arrows identify unusual, darkly staining foci;
small arrows identify peripheral, localized increases in epithelial density observed in some
PFOA-exposed animals at 18 months. On the right, histopathologic images from
contralateral glands in the same animal show ductal areas that might account for darkly
staining foci observed on whole mounts (400×; N = 4–11 females per treatment group at 18
months). The large arrow in GD 15–17 identifies an area of increased stromal density; the
small arrow points to a focus of inflammation. In GD 10–17 the arrow identifies a large,
potentially hyperplastic region of ductal epithelium. These ductal pathologies were observed
in all treatment groups; some ductal inflammation was also seen in controls.
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